Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0International Journal of Molecular Sciences

5-Azacytidine Reprograms Colorectal Cancer Cells Toward Senolytic Vulnerability and Enhanced T-Cell-Mediated Cytotoxicity

4 affiliations
  1. 1Department of Genetics and Life Sciences, Sirius University of Science and Technology, 354340 Sirius, Russia
  2. 2Institute of Cytology RAS, 194064 St. Petersburg, Russia
  3. 3French National Institute of Health and Medical Research, Joint Research Unit 1231, University of Burgundy, 21078 Dijon, France
  4. 4Institute of Urology and Clinical Oncology, Bashkir State Medical University, 450008 Ufa, Russia

Abstract

Aberrant DNA methylation is a hallmark of colorectal cancer (CRC) and represents a potential therapeutic target. DNA methyltransferase inhibitors can induce sustained transcriptional and phenotypic reprogramming of tumor cells; however, the therapeutic vulnerabilities created by this reprogramming are not completely understood. Here, we investigated the effects of 5-azacitidine (5-AZA) in the human CRC cell lines HT-29 and DLD-1 and assessed whether epigenetic priming could subsequently be exploited using senolytic or immunotherapeutic approaches. Treatment with 5-AZA reduced cell proliferation and induced a senescent phenotype accompanied by increased expression of the cyclin-dependent kinase inhibitors CDKN1A and CDKN2B and anti-apoptotic BCL-2 family proteins as well as p16 expression on protein level. These changes were most pronounced in HT-29 cells. Pretreatment with 5-AZA sensitized HT-29 cells to navitoclax, a broad-spectrum BH3 mimetic, whereas the selective BCL-2 inhibitor venetoclax was less effective. In DLD-1 cells, both the senescent phenotype and sensitization to navitoclax were less pronounced, indicating that the response to epigenetic priming is dependent on tumor-cell context. By contrast, in an in vitro immunotherapy model using DLD-1 tumor cells, lymphocytes and a bispecific CD19 × CD3 T-cell engager (BiTE), pretreatment of tumor cells with 5-AZA enhanced T-cell-mediated cytotoxicity and increased IFN-γ production. Thus, 5-AZA induces therapeutically relevant reprogramming of CRC cells, sensitizing them to navitoclax while simultaneously increasing their susceptibility to T-cell-mediated elimination. These findings provide a rationale for further investigation of sequential treatment strategies combining epigenetic priming with senolytic or immunotherapeutic approaches.

Related

  1. Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition
    Chiara Asselborn, Agata N Makar, Jair G Marques Junior +8
    eLifePeer-reviewedCC BY 4.0Full textGeneral biochemistryOncologyeLifeEurope PMCPMC
  2. Primary cilia disruption reprograms extracellular vesicle signaling in endothelial dysfunction and cardiovascular disease
    Megan Piquet, Sylvain Recoquillon, Rose Esnaud +3
    Life SciencesPeer-reviewedCC BY 4.0Full text1 citedMolecular biology & gene regulationHAL
  3. Transcription factor Fra-1 reprograms androgen receptor chromatin binding and super-enhancers in osteoblast differentiation
    Ken-ichi Takayama, Yutaka Suzuki, Shuichi Tsutsumi +2
    Journal of Biological ChemistryPeer-reviewedCC BY-NC-ND 4.0Molecular biology & gene regulationCrossref
  4. Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer
    Han Dong, Arindam Ray, Lara Rotter +20
    Nature ImmunologyPeer-reviewedPublisher termsFull text2 citedMolecular biology & gene regulationImmunologyHAL
  5. Acute degron-mediated RUNX1 loss reprograms enhancer activity associated with epithelial destabilization and initiation of cancer hallmarks
    Andrew J. Fritz, Haley Greenyer, Louis Dillac +29
    Cell ReportsPeer-reviewedCC BY-NC-ND 4.01 citedMolecular biology & gene regulationCrossref
BibTeX
@article{lisitsa20265azacytidine,
  title = {{5-Azacytidine Reprograms Colorectal Cancer Cells Toward Senolytic Vulnerability and Enhanced T-Cell-Mediated Cytotoxicity}},
  author = {Darya A. Lisitsa and Ekaterina D. Kolosova and Natalia A. Budkina and Viktoria M. Petrova and Oleg N. Demidov and Daria A. Bogdanova},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  month = nov,
  doi = {10.3390/ijms272210250},
  url = {https://www.mdpi.com/1422-0067/27/22/10250},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - 5-Azacytidine Reprograms Colorectal Cancer Cells Toward Senolytic Vulnerability and Enhanced T-Cell-Mediated Cytotoxicity
AU  - Darya A. Lisitsa
AU  - Ekaterina D. Kolosova
AU  - Natalia A. Budkina
AU  - Viktoria M. Petrova
AU  - Oleg N. Demidov
AU  - Daria A. Bogdanova
PY  - 2026
DA  - 2026/11/15
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms272210250
UR  - https://www.mdpi.com/1422-0067/27/22/10250
AB  - Aberrant DNA methylation is a hallmark of colorectal cancer (CRC) and represents a potential therapeutic target. DNA methyltransferase inhibitors can induce sustained transcriptional and phenotypic reprogramming of tumor cells; however, the therapeutic vulnerabilities created by this reprogramming are not completely understood. Here, we investigated the effects of 5-azacitidine (5-AZA) in the human CRC cell lines HT-29 and DLD-1 and assessed whether epigenetic priming could subsequently be exploited using senolytic or immunotherapeutic approaches. Treatment with 5-AZA reduced cell proliferation and induced a senescent phenotype accompanied by increased expression of the cyclin-dependent kinase inhibitors CDKN1A and CDKN2B and anti-apoptotic BCL-2 family proteins as well as p16 expression on protein level. These changes were most pronounced in HT-29 cells. Pretreatment with 5-AZA sensitized HT-29 cells to navitoclax, a broad-spectrum BH3 mimetic, whereas the selective BCL-2 inhibitor venetoclax was less effective. In DLD-1 cells, both the senescent phenotype and sensitization to navitoclax were less pronounced, indicating that the response to epigenetic priming is dependent on tumor-cell context. By contrast, in an in vitro immunotherapy model using DLD-1 tumor cells, lymphocytes and a bispecific CD19 × CD3 T-cell engager (BiTE), pretreatment of tumor cells with 5-AZA enhanced T-cell-mediated cytotoxicity and increased IFN-γ production. Thus, 5-AZA induces therapeutically relevant reprogramming of CRC cells, sensitizing them to navitoclax while simultaneously increasing their susceptibility to T-cell-mediated elimination. These findings provide a rationale for further investigation of sequential treatment strategies combining epigenetic priming with senolytic or immunotherapeutic approaches.
SN  - 1422-0067
ER  -